Acadian Asset Management LLC Buys 30,801 Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD)

Acadian Asset Management LLC raised its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 972.3% during the first quarter, HoldingsChannel.com reports. The firm owned 33,969 shares of the company’s stock after buying an additional 30,801 shares during the quarter. Acadian Asset Management LLC’s holdings in Oxford Immunotec Global were worth $586,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of OXFD. Vanguard Group Inc grew its stake in shares of Oxford Immunotec Global by 2.0% during the third quarter. Vanguard Group Inc now owns 95,647 shares of the company’s stock valued at $1,552,000 after buying an additional 1,839 shares during the last quarter. Northern Trust Corp grew its stake in shares of Oxford Immunotec Global by 0.7% during the fourth quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock valued at $3,715,000 after buying an additional 2,113 shares during the last quarter. Essex Investment Management Co. LLC grew its stake in shares of Oxford Immunotec Global by 2.0% during the fourth quarter. Essex Investment Management Co. LLC now owns 174,499 shares of the company’s stock valued at $2,230,000 after buying an additional 3,482 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Oxford Immunotec Global by 4.7% during the fourth quarter. New York State Common Retirement Fund now owns 77,631 shares of the company’s stock valued at $992,000 after buying an additional 3,500 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in shares of Oxford Immunotec Global by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock valued at $247,000 after buying an additional 5,120 shares during the last quarter. Institutional investors and hedge funds own 91.57% of the company’s stock.

In related news, CEO Peter Wrighton-Smith sold 10,600 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $16.68, for a total value of $176,808.00. Following the transaction, the chief executive officer now owns 445,138 shares of the company’s stock, valued at $7,424,901.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total value of $48,150.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $48,150. The disclosure for this sale can be found here. Corporate insiders own 6.61% of the company’s stock.

A number of research firms have recently commented on OXFD. Zacks Investment Research cut Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research note on Tuesday, March 26th. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $18.00.

OXFD opened at $14.55 on Wednesday. The company has a market cap of $393.49 million, a PE ratio of 28.53 and a beta of 0.42. Oxford Immunotec Global PLC has a one year low of $11.66 and a one year high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. The firm had revenue of $14.79 million for the quarter, compared to analysts’ expectations of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The company’s quarterly revenue was up 26.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. As a group, equities research analysts predict that Oxford Immunotec Global PLC will post -0.28 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Acadian Asset Management LLC Buys 30,801 Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD)” was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.wkrb13.com/2019/06/12/acadian-asset-management-llc-buys-30801-shares-of-oxford-immunotec-global-plc-nasdaqoxfd.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Read More: Trading Options- What is a Strangle?

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.